Cargando…

A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications

BACKGROUND: Autotransplantation of cryopreserved ovarian cortex can be associated with a risk of cancer cell reseeding. This issue could be eliminated by grafting isolated preantral follicles. Collagenase NB6 is an enzyme produced under good manufacturing practices (GMP) in compliance with requireme...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouloungui, Elodie, Zver, Tristan, Roux, Christophe, Amiot, Clotilde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756359/
https://www.ncbi.nlm.nih.gov/pubmed/29304838
http://dx.doi.org/10.1186/s13048-017-0376-6
_version_ 1783290712866947072
author Mouloungui, Elodie
Zver, Tristan
Roux, Christophe
Amiot, Clotilde
author_facet Mouloungui, Elodie
Zver, Tristan
Roux, Christophe
Amiot, Clotilde
author_sort Mouloungui, Elodie
collection PubMed
description BACKGROUND: Autotransplantation of cryopreserved ovarian cortex can be associated with a risk of cancer cell reseeding. This issue could be eliminated by grafting isolated preantral follicles. Collagenase NB6 is an enzyme produced under good manufacturing practices (GMP) in compliance with requirements for tissue engineering and transplantation in humans and thus can be used to isolate preantral follicles from ovarian tissue in the framework of further clinical applications. Multicolor flow cytometry is an effective tool to evaluate the potential contamination of follicular suspensions by leukemic cells. METHODS: The efficiency of collagenase NB6 was evaluated in comparison to collagenase type IA and Liberase DH, in terms of yield, morphology and viability. A short-term in vitro culture of follicles isolated with collagenase NB6 was conducted for 3 days in a fibrin matrix. A modelization procedure was carried out to detect the presence of leukemic cells in follicular suspensions using multicolor flow cytometry (MFC). RESULTS: No statistical differences were found between collagenase NB6, Liberase DH (p = 0.386) and collagenase type IA (p = 0.171) regarding the number of human preantral follicles isolated. The mean diameter of isolated follicles was significantly lower with collagenase NB6 (p < 0.0001). The survival rate of isolated follicles was 93.4% (n = 272) using collagenase NB6 versus 94.9% (n = 198) with Liberase DH and 92.6% (n = 298) using collagenase type IA. Even after 3 days of in vitro culture in a fibrin scaffold, most of the isolated follicles were still alive after using collagenase NB6 (90.7% of viable follicles; n = 339). The rate of isolated Ki67-positive follicles was 29 ± 9.19% before culture and 45 ± 1.41% after 3 days. In 23 out of 24 follicular suspensions analyzed, the detection of leukemic cells by MFC was negative. The purification had no significant impact on follicle viability. CONCLUSION: The isolation and purification of human preantral follicles were performed following good manufacturing practices for cell therapy. Multicolor flow cytometry was able to confirm that final follicular suspensions were free from leukemic cells. This safe isolation technique using collagenase NB6 can be considered for future clinical applications.
format Online
Article
Text
id pubmed-5756359
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57563592018-01-08 A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications Mouloungui, Elodie Zver, Tristan Roux, Christophe Amiot, Clotilde J Ovarian Res Research BACKGROUND: Autotransplantation of cryopreserved ovarian cortex can be associated with a risk of cancer cell reseeding. This issue could be eliminated by grafting isolated preantral follicles. Collagenase NB6 is an enzyme produced under good manufacturing practices (GMP) in compliance with requirements for tissue engineering and transplantation in humans and thus can be used to isolate preantral follicles from ovarian tissue in the framework of further clinical applications. Multicolor flow cytometry is an effective tool to evaluate the potential contamination of follicular suspensions by leukemic cells. METHODS: The efficiency of collagenase NB6 was evaluated in comparison to collagenase type IA and Liberase DH, in terms of yield, morphology and viability. A short-term in vitro culture of follicles isolated with collagenase NB6 was conducted for 3 days in a fibrin matrix. A modelization procedure was carried out to detect the presence of leukemic cells in follicular suspensions using multicolor flow cytometry (MFC). RESULTS: No statistical differences were found between collagenase NB6, Liberase DH (p = 0.386) and collagenase type IA (p = 0.171) regarding the number of human preantral follicles isolated. The mean diameter of isolated follicles was significantly lower with collagenase NB6 (p < 0.0001). The survival rate of isolated follicles was 93.4% (n = 272) using collagenase NB6 versus 94.9% (n = 198) with Liberase DH and 92.6% (n = 298) using collagenase type IA. Even after 3 days of in vitro culture in a fibrin scaffold, most of the isolated follicles were still alive after using collagenase NB6 (90.7% of viable follicles; n = 339). The rate of isolated Ki67-positive follicles was 29 ± 9.19% before culture and 45 ± 1.41% after 3 days. In 23 out of 24 follicular suspensions analyzed, the detection of leukemic cells by MFC was negative. The purification had no significant impact on follicle viability. CONCLUSION: The isolation and purification of human preantral follicles were performed following good manufacturing practices for cell therapy. Multicolor flow cytometry was able to confirm that final follicular suspensions were free from leukemic cells. This safe isolation technique using collagenase NB6 can be considered for future clinical applications. BioMed Central 2018-01-05 /pmc/articles/PMC5756359/ /pubmed/29304838 http://dx.doi.org/10.1186/s13048-017-0376-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mouloungui, Elodie
Zver, Tristan
Roux, Christophe
Amiot, Clotilde
A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
title A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
title_full A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
title_fullStr A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
title_full_unstemmed A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
title_short A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
title_sort protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756359/
https://www.ncbi.nlm.nih.gov/pubmed/29304838
http://dx.doi.org/10.1186/s13048-017-0376-6
work_keys_str_mv AT moulounguielodie aprotocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT zvertristan aprotocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT rouxchristophe aprotocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT amiotclotilde aprotocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT moulounguielodie protocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT zvertristan protocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT rouxchristophe protocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications
AT amiotclotilde protocoltoisolateandqualifypurifiedhumanpreantralfolliclesincasesofacuteleukemiaforfutureclinicalapplications